Barclays’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-110,787
| Closed | -$3.74M | – | 5136 |
|
|
2021
Q2 | $3.74M | Buy |
110,787
+44,516
| +67% | +$1.13M | ﹤0.01% | 1767 |
|
|
2021
Q1 | $1.55M | Sell |
66,271
-34,302
| -34% | -$1.04M | ﹤0.01% | 2493 |
|
|
2020
Q4 | $2.9M | Sell |
100,573
-3,920
| -4% | -$98.7K | ﹤0.01% | 1951 |
|
|
2020
Q3 | $2.12M | Buy |
104,493
+66,317
| +174% | +$1.62M | ﹤0.01% | 2045 |
|
|
2020
Q2 | $1.15M | Buy |
38,176
+11,494
| +43% | +$414K | ﹤0.01% | 2634 |
|
|
2020
Q1 | $838K | Buy |
26,682
+8,346
| +46% | +$290K | ﹤0.01% | 3136 |
|
|
2019
Q4 | $863K | Buy |
18,336
+10,616
| +138% | +$306K | ﹤0.01% | 3806 |
|
|
2019
Q3 | $50K | Sell |
7,720
-2,346
| -23% | -$19.6K | ﹤0.01% | 5911 |
|
|
2019
Q2 | $123K | Buy |
10,066
+5,590
| +125% | +$62.2K | ﹤0.01% | 5530 |
|
|
2019
Q1 | $61K | Buy |
+4,476
| New | +$40.1K | ﹤0.01% | 5734 |
|
|
2018
Q4 | – | Sell |
-1,512
| Closed | -$10K | – | 7556 |
|
|
2018
Q3 | $10K | Buy |
+1,512
| New | +$14.4K | ﹤0.01% | 6663 |
|
Barclays's CNST Position: Q3 2021 in Review
Barclays sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 110,787 shares — an estimated $3.74M sold.
Barclays first reported a position in CNST in Q3 2018 and held it in 11 quarters. The position peaked at $3.74M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Barclays reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Barclays sold 110,787 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $3.74M.
- Barclays first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 11 quarters.
- Barclays's Constellation Pharmaceuticals, Inc. position peaked at $3.74M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.